Information:
Fel:
ID
30801
Beskrivning
Study part: Treatment confirmation. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.
Nyckelord
Versioner (1)
- 2018-06-20 2018-06-20 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
20 juni 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Treatment confirmation Pazopanib Macular Degeneration MD1103367
Similar models
Treatment confirmation
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
TREATMENT CONFIRMATION (Trt Cont)
C0087111 (UMLS CUI-1)
C0750484 (UMLS CUI-2)
C0750484 (UMLS CUI-2)
Item
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
text
C1522541 (UMLS CUI [1])
Code List
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
CL Item
Yes (Y)
CL Item
No (N)
reason therapy assigned
Item
When no, record reason
text
C0392360 (UMLS CUI [1,1])
C1522541 (UMLS CUI [1,2])
C1522541 (UMLS CUI [1,2])